Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway

Ayres, Flávio Monteiro; Narita, Minoru; Takahashi, Masuhiro; Yano, Toshio; Liu, Aichun; Toba, Kenji; Furukawa, Tatsuo; Aizawa, Yoshifusa

doi:10.3892/or.11.5.1017

Cited by 9 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in our study, the marginal expression of FasL and no change of TNF-α, either on the surface or in the cytoplasm of CBDC stimulated with LPS or IFN-γ, makes TNFα-and Fas-apoptosis pathway unlikely, as reported for adult DC. (26,27) The findings presented in this article have shown that LPS-or IFN-stimulated DC exhibited the different tumoricidal activity against the same target cells. CBDC stimulated by IFN-γ leads to an increase of cytotoxicity against HL60, but not against Daudi, whereas LPS stimulated-DC exhibits the completely opposite results (Fig.…”

Section: Discussionmentioning

confidence: 87%

Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 87%

Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells

et al. 2005

View full text Add to dashboard Cite

“…While the demonstration of direct DCmediated killing of tumor cells in vivo is a technically daunting agenda, intra-tumoral injection of DC or treatment of tumors with DC-activating factors has been shown to correlate with reduced tumor growth and even regression. 9,10,12,21,35,46 Clearly such anti-tumor activity could prove the result of KDC activity, but it could equally well involve DC-induced tumoristatic/antiangiogenic properties 34,43 and/or the ability of lesion associated DC to activate effector NK and T cells that could themselves mediate tumor cell death. 32 Studies of DCmediated tumor apoptosis in T/NK-deficient hosts could prove instrumental in visualizing direct killing of tumor cells in situ by DC; although it is likely that tumor regression would not be observed under these conditions, since both T and NK would likely be required for complete tumor eradication.…”

Section: Dc-mediated Tumoricidal Activity In Vivomentioning

confidence: 99%

Killer dendritic cells: mechanisms of action and therapeutic implications for cancer

Wesa

Storkus

2007

Cell Death Differ

View full text Add to dashboard Cite

Dendritic cells (DC) are essential for the development and regulation of adaptive host immune responses against tumors. DC are heterogeneous and comprised of diverse cellular subsets. They are best known for mediating a crucial role in the initiation of acquired immunity by serving as professional antigen presenting cells (APC) that take up antigens in their local microenvironment, which are then processed and presented to naïve T cells in the context of major histocompatibility complex (MHC) class I and II molecules. In addition to these functions, DC can modulate the types of T cell responses they generate, and can also influence the responses of innate effectors, such as NK cells. There is also now evidence that they may mediate a more primordial role as innate, effector cells that are tumoricidal. 'Killer' DC (KDC) may represent a true 'multi-tasking' cell type that can sequentially act as a 'hunter-gatherer' of antigens; as well as, an instructor, then enforcer/regulator, of antigenspecific anti-tumor T-cell responses in vivo. In this review, we will critically examine the published record regarding KDC, their mechanism(s) of action, and then consider the potential integration of KDC into novel immunotherapies for patients with cancer.

show abstract

“…The mode of tumor cell killing by DCs may involve the death receptor family and their ligands (6, 8, 10–13, 15, 17–20, 25, 31), perforin and granzyme (8), or as we previously reported NO or peroxynitrites (4, 11, 23, 26, 27). NO has been shown to sensitize tumor cells to Fas-ligand-mediated killing by immature or spontaneously matured DC (9).…”

Section: Discussionmentioning

confidence: 91%

Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism

LaCasse

Janikashvili

Larmonier

et al. 2011

The Journal of Immunology

View full text Add to dashboard Cite

Dendritic cells (DCs) encompass a heterogeneous population of cells capable of orchestrating innate and adaptive immune responses. The ability of DCs to act as professional antigen presenting cells has been the foundation for the development and utilization of these cells as vaccines in cancer immunotherapy. DCs are also endowed with the non-conventional property of directly killing tumor cells. The current study investigates the regulation of murine DC cytotoxic function by T lymphocytes. We provide evidence that CD4+ Th-1, but not Th-2, Th-17 cells or Treg are capable of inducing DC cytotoxic function. IFN-γ was identified as the major factor responsible for Th-1-induced DC tumoricidal activity. Tumor cell killing mediated by Th-1-activated killer DCs (Th-1 KDCs) was dependent on inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production. Importantly, Th-1 KDCs were capable of presenting the acquired antigens from the killed tumor cells to T lymphocytes in vitro or in vivo. These observations open new possibilities for the application of KDCs in cancer immunotherapy.

show abstract

Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway

Cited by 9 publications

References 0 publications

Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells

Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells

Killer dendritic cells: mechanisms of action and therapeutic implications for cancer

Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism

Contact Info

Product

Resources

About